Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Weber, one of the highest-profile foreign CEOs in Japan, spearheaded Takeda's $59 billion takeover of British-founded Shire ...

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...

The presentation of Japanese drugmaker Takeda’s latest financial results were presented Thursday, though they took a back ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

Suffolk, one of the largest and most innovative real estate and construction enterprises in the country, recently celebrated topping off 585 Kendall. Designed by CBT Architects, 585 Kendall is a mixed ...

In a long-term succession plan, the board of directors at Japan’s largest drugmaker Takeda has made the decision unanimously ...

PersonnelTakeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 202630-Jan-2025 / 09:31 CET/CESTDisclosure of an inside information acc. to Article 17 ...

Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process ...

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

BioMed Realty, a Blackstone portfolio company and the largest private operator of life science real estate, alongside Suffolk ...